<DOC>
	<DOCNO>NCT00777790</DOCNO>
	<brief_summary>This study design evaluate antibody response Menactra® booster dose participant previously receive one dose Menactra® Menomune® adolescents 3 year earlier Study MTA02 . Primary Objective : To evaluate antibody response booster dose tetravalent meningococcal diphtheria toxoid conjugate vaccine ( Menactra® ) participants previously receive Menactra® Menomune® adolescent MTA02 Study antibody response dose Menactra® naive adolescent .</brief_summary>
	<brief_title>Study Booster Dose Meningococcal Diphtheria Toxoid Conjugate Vaccine Adolescents</brief_title>
	<detailed_description>All subject give single boost dose Menactra® evaluate kinetics response , magnitude avidity antibody produce .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Participant healthy , determined medical history physical examination . Participant least 13 year age yet 22 year age time enrollment . For Menactra® Menomune® group , participant receive one dose Menactra® Menomune® MTA02 trial complete trial ( 2 blood sample , contact Month 6 safety follow ) . For Control group , participant previous history meningococcal vaccination . If &lt; 18 year age , participant sign Institutional Review Board ( IRB ) approve informed assent form his/her parent/legal guardian sign IRBapproved informed consent form . If ≥ 18 year age , participant sign IRBapproved inform consent form . Able provide vaccination log . Exclusion Criteria : Serious chronic disease ( i.e. , cardiac , renal , neurologic , metabolic , rheumatologic , psychiatric etc ) . Known suspected impairment immunologic function . Acute medical illness without fever within last 72 hour oral temperature ≥ 100.4ºF ( ≥ 38.0ºC ) time inclusion . For Menactra® Menomune® group , history document invasive meningococcal disease previous meningococcal vaccination exception meningococcal vaccination give part MTA02 trial . For Control group , history document invasive meningococcal disease previous meningococcal vaccination . Administration immune globulin , blood product within last three month , injected oral corticosteroid immunomodulatory therapy within six week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive one course within last two week prior enrollment . Antibiotic therapy within 72 hour prior vaccination antibiotic therapy within 72 hour prior blood sample drawn . Received vaccine 14day period prior study vaccination , schedule receive vaccination 14day period study vaccination . Suspected known hypersensitivity vaccine component . Unavailable entire study period unable attend schedule visit comply study procedure . In female , positive equivocal urine pregnancy test time vaccination . Enrolled another clinical trial . Any condition , , opinion investigator , would pose health risk participant , interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcemia</keyword>
	<keyword>Neisseria meningitidis</keyword>
</DOC>